[HTML][HTML] Going the extra (synaptic) mile: excitotoxicity as the road toward neurodegenerative diseases

A Armada-Moreira, JI Gomes, CC Pina… - Frontiers in cellular …, 2020 - frontiersin.org
Excitotoxicity is a phenomenon that describes the toxic actions of excitatory
neurotransmitters, primarily glutamate, where the exacerbated or prolonged activation of …

[HTML][HTML] Neuronal excitation/inhibition imbalance: core element of a translational perspective on Alzheimer pathophysiology

F Maestú, W de Haan, MA Busche, J DeFelipe - Ageing Research Reviews, 2021 - Elsevier
Our incomplete understanding of the link between Alzheimer's Disease pathology and
symptomatology is a crucial obstacle for therapeutic success. Recently, translational studies …

The preclinical phase of the pathological process underlying sporadic Alzheimer's disease

H Braak, K Del Tredici - Brain, 2015 - academic.oup.com
Abnormal tau lesions (non-argyrophilic pretangle material, argyrophilic neuropil threads,
neurofibrillary tangles) in select types of neurons are crucial for the pathogenesis of sporadic …

Functional cognitive disorder: dementia's blind spot

HA Ball, L McWhirter, C Ballard, R Bhome… - Brain, 2020 - academic.oup.com
An increasing proportion of cognitive difficulties are recognized to have a functional cause,
the chief clinical indicator of which is internal inconsistency. When these symptoms are …

Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence

J Tomé-Carneiro, M Larrosa… - Current …, 2013 - ingentaconnect.com
Resveratrol (3, 5, 4'-trihydroxy-trans-stilbene) is a non-flavonoid polyphenol that may be
present in a limited number of foodstuffs such as grapes and red wine. Resveratrol has been …

[HTML][HTML] Mechanisms of Alzheimer's disease pathogenesis and prevention: the brain, neural pathology, N-methyl-D-aspartate receptors, tau protein and other risk …

S Kocahan, Z Doğan - Clinical Psychopharmacology and …, 2017 - ncbi.nlm.nih.gov
The characteristic features of Alzheimer's disease (AD) are the appearance of extracellular
amyloid-beta (Aβ) plaques and neurofibrillary tangles in the intracellular environment …

[HTML][HTML] Is dopamine involved in Alzheimer's disease?

A Martorana, G Koch - Frontiers in aging neuroscience, 2014 - frontiersin.org
Alzheimer's Disease (AD) is a neurodegenerative disorder characterized by progressive
cognitive decline and dementia. Recent advances indicate that AD pathogenesis appears …

The impact of obesity on neurodegenerative diseases

JN Mazon, AH de Mello, GK Ferreira, GT Rezin - Life sciences, 2017 - Elsevier
Neurodegenerative diseases are a growing health concern. The increasing incidences of
these disorders have a great impact on the patients' quality of life. Although the mechanisms …

Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic

E Aso, I Ferrer - Frontiers in pharmacology, 2014 - frontiersin.org
The limited effectiveness of current therapies against Alzheimer's disease (AD) highlights
the need for intensifying research efforts devoted to developing new agents for preventing or …

Hypothesis review: Alzheimer's overture guidelines

I Ferrer - Brain Pathology, 2023 - Wiley Online Library
Abstract National Institute on Aging–Alzheimer's Association definition and classification of
sporadic Alzheimer's disease (sAD) is based on the assumption that β‐amyloid drives the …